首页> 外文期刊>Journal of Breast Cancer >Expression of estrogen receptor β, estrogen receptor α and cyclooxygenase II in advanced breast cancer
【24h】

Expression of estrogen receptor β, estrogen receptor α and cyclooxygenase II in advanced breast cancer

机译:雌激素受体β,雌激素受体α和环氧合酶II在晚期乳腺癌中的表达

获取原文
           

摘要

Purpose Although the role of the estrogen receptor α (ERα, previously called the estrogen receptor) in breast cancer is well established, that of the second human estrogen receptor (ER), estrogen receptorβ (ERβ), remains uncertain, The expression of cyclooxygenase II (COX II) could also be regulated by sex steroids such as estrogen and progesterone. To investigate whether the expressions of the ERβ, ERα, and COX II are elevated in more aggressive breast cancers, the expression of the ERβ was studied by immunohistochemical staining in 20 primary breast cancer and original breast cancer tissues from 20 recurrent cancer patients, and its associations with ERα and cyclooxygenase (COX) II were evaluated. Methods Paraffin tissue sections from 40 breast cancers. surgically excised at the Department of Surgery, the Catholic University of Korea. were obtained. The immunohistochemical analysis was conducted on 20 non-recurrent, and 20 recurrent primary breast cancer tissues, using polyclonal antibodies to ERβ, ERα, and the corresponding monoclonal antibodies to COX II. Results Of the 40 patients, 15 (37.5%) were ERβ-positive. 30 (75%) were ERα-positive, and 24 (60%) were COX II-positive, The ERβ status was not related to the tumor size or menopausal status, but was related to the nodal status, The stati of ERα and COX II were not related to other clinico-pathological factors, The ERβ positivity was significantly more frequent in the study than the control group. (ERβ, p = 0.0222; ERα p = 0.1441; COX II, P = 100) The presence of ERβ was significantly related to the expression of ERα and COX II ( p = 0.0455, P = 0.0381, respectively). Conclusion These results suggest that the expression of ERβ is associated with early recurrence in breast cancer and the expression of COX II in the presence of ERβ implies the possibility of prognostic significance.
机译:目的尽管雌激素受体α(ERα,以前称为雌激素受体)在乳腺癌中的作用已得到公认,但第二种人类雌激素受体(ER)雌激素受体β(ERβ)的作用仍不确定,环氧合酶II的表达(COX II)也可以通过雌激素和孕激素等性类固醇调节。为了研究在更具侵略性的乳腺癌中ERβ,ERα和COX II的表达是否升高,通过免疫组织化学染色研究了20例复发性癌症患者的20例原发性乳腺癌和原始乳腺癌组织中ERβ的表达,评估与ERα和环氧合酶(COX)II的关联。方法从40例乳腺癌中提取石蜡组织切片。韩国天主教大学外科系手术切除。获得了。使用针对ERβ,ERα的多克隆抗体和针对COX II的相应单克隆抗体,对20个非复发性和20个复发性原发性乳腺癌组织进行了免疫组织化学分析。结果40例患者中,ERβ阳性15例(37.5%)。 ERα阳性的有30(75%),COX II阳性的有24(60%),ERβ的状态与肿瘤的大小或绝经状态无关,而与淋巴结的状态,ERα和COX的状态有关II与其他临床病理因素无关,研究中的ERβ阳性率明显高于对照组。 (ERβ,p = 0.0222;ERα,p = 0.1441; COX II,P = 100)ERβ的存在与ERα和COX II的表达显着相关(分别为p = 0.0455,P = 0.0381)。结论这些结果提示ERβ的表达与乳腺癌的早期复发有关,而ERβ存在时COX II的表达暗示了预后的可能性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号